By HotStockRockets | Sunday 20 March 2016
Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Optibiotix (OPTI) shares trade at 69p-70p having slipped on news yesterday which was "the wrong sort of good news". Fear not. The right sort is imminent. The wrong good news was that it has set up a 52% owned JV with the University of Manchester called SkinBiotix. Optibiotix says that:
The University of Manchester has an international reputation for its research into skin diseases and is one of Europe's leading dermatology clinical trial units. This agreement brings together the University's intellectual property and research expertise in skin health with OptiBiotix's microbiome modulating expertise and commercial focus.
OptiBiotix has a strategy to partner with multiple organisations and this JV agreement accelerates OptiBiotix's plan of extending its Optiscreen® and OptiBiotix® technology platforms into new application areas. The Company believes modulating the skin microbiome to treat chronic skin health problems provides significant growth opportunities and the potential for new partnering and product opportunities.
Optibiotix is investing £260,000 for its stake. This could be interesting long term. In the end we'd hope to see this spun off to create real value. Short term however what folks want is commercial deals on core products, notably sugar alternatives in light of the recent budget. We do not expect to have to wait very long at all. And that will drive a big re-rate.
Average down and buy.
Never miss a story.
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |